• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nu Skin Ranked the World's #1 Company for Beauty and Wellness Device Systems

    7/30/24 8:00:00 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email

    Nu Skin Enterprises Inc. (NYSE:NUS), a global beauty and wellness leader, has been ranked the world's No. 1 company for beauty and wellness device systems by Euromonitor International Ltd., which publishes the world's most comprehensive market research on the skin care industry. Nu Skin is the world's best-selling beauty and wellness device system company based on Euromonitor's custom research and methodology conducted April to May 2024.*

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730332637/en/

    Nu Skin's family of beauty and wellness devices: ageLOC LumiSpa iO, Nu Skin RenuSpa iO, Nu Skin Facial Spa, and ageLOC Boost (Not all products are available in all markets). (Photo: Business Wire)

    Nu Skin's family of beauty and wellness devices: ageLOC LumiSpa iO, Nu Skin RenuSpa iO, Nu Skin Facial Spa, and ageLOC Boost (Not all products are available in all markets). (Photo: Business Wire)

    "We continue to be thrilled by the growth of our connected device community and how it elevates Nu Skin as the leader in the rapidly growing at-home beauty and wellness device market," said Steve Hatchett, EVP and Chief Product Officer at Nu Skin. "Nu Skin's broad portfolio of advanced, proprietary and personalized device systems offers simple, powerful and smart beauty and wellness solutions. Our scientifically developed serums and treatments enhance the performance of our devices, giving users faster and more effective results. Consumers can enjoy the convenience of using these beauty and wellness devices at home to get clinically proven results."

    Nu Skin offers an award-winning portfolio of beauty and wellness devices:

    • ageLOC® LumiSpa® iO is a smart skin treatment and cleansing device that delivers brighter, healthier and more youthful-looking skin with a spa-like experience in just two minutes, twice a day. Featuring Nu Skin's patented micropulse oscillation technology, the ageLOC LumiSpa iO system takes personalized beauty to a new level with customized treatment options, intelligent coaching, skincare routine tracking and more. The one-of-a-kind ageLOC LumiSpa iO, along with its predecessor ageLOC LumiSpa, have received more than 50 global awards, including awards from Cosmopolitan, NewBeauty, Edison, BELLA Magazine, the Global Makeup Awards and Good Design.
    • Nu Skin® RenuSpa iO™ is the company's first integrated beauty and wellness device in the U.S. RenuSpa iO is an FDA-cleared microcurrent body device that helps to restore wellbeing, revitalize your appearance and refresh your body through skin stimulation. The device uses patent-pending adaptive microcurrent technology that continuously adapts (more than 80 times per second) to your skin's conductivity throughout each session. The patent-pending design of the metallic nodes on the device help provide a smooth, comfortable massage. Designed for use on the upper and lower legs, arms and abdomen, the nodes are designed to perfectly fit the contours of your body and glide smoothly over your skin. Since its launch in February 2024, the device has won five awards for its innovative use of adaptive microcurrent technology.
    • ageLOC® WellSpa iO™ is the company's first integrated beauty and wellness device for more than 40 global markets, designed to deliver the power of overall wellness, body confidence and rejuvenation. Launched in the fall of 2023, this smart device helps to restore wellbeing, revitalize your appearance and recover from an active lifestyle. WellSpa iO has won several global awards in 2024, including a gold Universal Beauty Award for "Best Body Device," a BIG Innovation Award and a gold Globee Award for Disruptors. (Not sold in the US).

    The Nu Skin device family also includes ageLOC Galvanic Spa®, ageLOC Body Spa, Nu Skin Facial Spa, ageLOC Boost and ageLOC Me® to address a range of top skin care concerns such as brightness, firming, hydrating and the appearance of lines and wrinkles (devices are not available in all markets).

    For more information about Nu Skin beauty and wellness products, visit www.nuskin.com.

    About Nu Skin Enterprises

    The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

    *Source Euromonitor International Limited: At-Home Beauty and Wellness Device Systems on a total retail level in RSP, excluding salon services that may offer packages; research conducted April – May 2024.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240730332637/en/

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, President of Global Sales Keisel Justin S covered exercise/tax liability with 1,534 shares, decreasing direct ownership by 1% to 126,798 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    2/18/26 4:36:11 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith covered exercise/tax liability with 10,763 shares, decreasing direct ownership by 5% to 208,878 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    2/18/26 4:33:46 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    EVP and General Counsel Clark Chayce David covered exercise/tax liability with 17,947 shares, decreasing direct ownership by 6% to 297,277 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    2/18/26 4:32:03 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    SEC Filings

    View All

    SEC Form 10-K filed by Nu Skin Enterprises Inc.

    10-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    2/12/26 9:49:18 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    2/12/26 4:23:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form SCHEDULE 13G filed by Nu Skin Enterprises Inc.

    SCHEDULE 13G - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    2/12/26 3:19:55 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance

    Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year's end Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025. Executive Summary Q4 2025 vs. Prior-year Quarter Revenue $370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million Earnings Per Share (EPS) $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges Customers 748,796; (10)% Paid Affiliates 129,311; (11)% Sales Leaders 30,045; (

    2/12/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Mar. 11, 2026, to shareholders of record on Feb. 27, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal ca

    2/12/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Dr. Joseph Chang Launches Update to Bestselling Book "The Aging Myth" With 15 More Years of Breakthrough Research on Cellular Wellness

    The updated edition of the New York Times bestseller from the chair of the Nu Skin Scientific Advisory Board reveals latest science behind measurable biology and evidence-based longevity Nu Skin Enterprises Inc. (NYSE:NUS) today announced the relaunch of "The Aging Myth: Unlocking the Mysteries of Looking and Feeling Young," the updated edition of the bestselling book from Dr. Joseph Chang, chair of Nu Skin's Scientific Advisory Board. The relaunch marks a significant milestone in the evolution of evidence-based beauty and wellness, bringing together decades of research that underpin Nu Skin's science-led innovations — from ageLOC® technology to the company's intelligent beauty and wellne

    2/6/26 1:56:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

    DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

    2/17/22 4:46:52 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

    Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

    11/24/21 11:03:39 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints James Winett to Board of Directors

    Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

    6/2/25 12:19:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

    Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

    9/12/24 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NUS
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance

    Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year's end Nu Skin Enterprises Inc. (NYSE:NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025. Executive Summary Q4 2025 vs. Prior-year Quarter Revenue $370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue (0.2)% FX impact or $(0.8) million Earnings Per Share (EPS) $0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges Customers 748,796; (10)% Paid Affiliates 129,311; (11)% Sales Leaders 30,045; (

    2/12/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Mar. 11, 2026, to shareholders of record on Feb. 27, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal ca

    2/12/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce Fourth Quarter and Full Year 2025 Financial Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced it will release fourth quarter and full year 2025 results after the market closes on Thursday, Feb. 12. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Feb. 26. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (

    1/14/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care